高级检索
当前位置: 首页 > 详情页

High expression of citron kinase predicts poor prognosis of prostate cancer.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Urology, The First Affiliated Hospital of Chongqing Medical University [2]Department of Urology, The People's Hospital of Dazu [3]First Clinical Institute, Chongqing Medical University, Chongqing 400016 [4]Department of Urology, The Zigong No. 4 People's Hospital [5]Department of Urology, The Zigong No. 1 People's Hospital, Zigong, Sichuan 643000 [6]Gastroenterology and Neurology Center, University‑Town Hospital of Chongqing Medical University [7]College of Life Science, Chongqing Medical University, Chongqing 400016, P.R. China
出处:
ISSN:

关键词: prostate cancer citron kinase prognosis

摘要:
Citron kinase (CIT) is a Rho-effector protein kinase that is associated with several types of cancer. However, the role of CIT in prostate cancer (PCa) is unclear. The current study utilized microarray data obtained from The Cancer Genome Atlas, which was analyzed via Biometric Research Program array tools. Additionally, reverse transcription-quantitative (RT-q)PCR was performed to compare the mRNA expression of CIT in PCa tissue and in benign prostatic hyperplasia. The protein expression of CIT was detected in a consecutive cohort via immunochemistry and CIT was screened as a potential oncogene in PCa. The results of RT-qPCR demonstrated that the mRNA expression of CIT was increased in PCa tissues. Furthermore, immunochemistry revealed that CIT protein expression was positively associated with age at diagnosis, Gleason grade, serum PSA, clinical T stage, risk group, lymph node invasion and metastasis. When compared with the low expression group, patients with a high CIT expression exhibited shorter survival rates, cancer specific mortalities (CSM) and biochemical recurrence (BCR). In addition, multivariate analysis revealed that CIT was a potential predictor of CSM and BCR. The results revealed that CIT is overexpressed during the malignant progression of PCa and may be a predictor of a poor patient prognosis. Copyright: © Liu et al.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2020]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Department of Urology, The First Affiliated Hospital of Chongqing Medical University
共同第一作者:
通讯作者:
通讯机构: [1]Department of Urology, The First Affiliated Hospital of Chongqing Medical University [*1]Department of Urology, The First Affiliated Hospital of Chongqing Medical University, 1 Yixueyuan Road, Chongqing 400016, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:46895 今日访问量:0 总访问量:3333 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号